Export

EN
FR
Rasburicase
Essential medicine status
Section:
8. Immunomodulators and antineoplastics 8.2. Antineoplastics and supportive medicines 8.2.5. Supportive medicines
ATC codes: V03AF07
EMLc
Indication
Tumour lysis syndrome ICD11 code: 5C70
INN
Rasburicase
Medicine type
Biological agent
List type
Complementary (EML)
(EMLc)
Formulations
Parenteral > General injections > IV: 1.5 mg in vial powder and 1 mL solvent for solution ; 7.5 mg in vial powder and 5 mL solvent for solution
EML status history
First added in 2021 (TRS 1035)
Changed in 2025 (TRS 1064)
Sex
All
Age
Also recommended for children
Therapeutic alternatives
The recommendation is for this specific medicine
Patent information
Patents have expired in most jurisdictions
Tags
Wikipedia
Rasburicase
DrugBank
Rasburicase
Summary of evidence and Expert Committee recommendations
Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - to modify the formulation descriptions to better describe the available dosage forms.